TY - JOUR
T1 - Homocysteine and cognitive impairment in Parkinson's disease
T2 - A biochemical, neuroimaging, and genetic study
AU - Rodriguez-Oroz, Maria C.
AU - Lage, Pablo Martínez
AU - Sanchez-Mut, Jose
AU - Lamet, Isabel
AU - Pagonabarraga, Javier
AU - Toledo, Jon B.
AU - García-Garcia, David
AU - Clavero, Pedro
AU - Samaranch, Lluis
AU - Irurzun, Cecilia
AU - Matsubara, Juan M.
AU - Irigoien, Jaione
AU - Bescos, Emilia
AU - Kulisevsky, Jaime
AU - Pérez-Tur, Jordi
AU - Obeso, Jose A.
PY - 2009/7/30
Y1 - 2009/7/30
N2 - The role of the plasma level of homocysteine (Hcy), as a primary outcome, and the effect of silent cerebro-vascular lesions and genetic variants related to Hcy metabolism, as secondary outcomes, in the cognitive decline and dementia in Parkinson's disease (PD) were studied. This case-control study focused on 89 PD patients of minimum 10 years of evolution and older than 60 years, who were neuropsychologically classified either as cognitively normal (n = 37), having mild cognitive impairment (Petersen criteria) (n = 22), or suffering from dementia (DSM-IV) (n = 30), compared with cognitively normal age-matched control subjects (n = 30). Plasma levels of Hcy, vitamins B12 and B6, folic acid, polymorphisms in genes related to Hcy metabolism (MTHFR, MTR, MTRR, and CBS) and silent cerebrovascular events were analyzed. Plasma levels of Hcy were increased in PD patients (P = 0.0001). There were no differences between the groups of patients. The brain vascular burden was similar among PD groups. There was no association between polymorphisms in the studied genes and the Hcy plasma levels or cognitive status in PD patients. We found no evidence for a direct relationship between Hcy plasma levels and cognitive impairment and dementia in PD. No indirect effect through cerebrovascular disease or genetic background was found either.
AB - The role of the plasma level of homocysteine (Hcy), as a primary outcome, and the effect of silent cerebro-vascular lesions and genetic variants related to Hcy metabolism, as secondary outcomes, in the cognitive decline and dementia in Parkinson's disease (PD) were studied. This case-control study focused on 89 PD patients of minimum 10 years of evolution and older than 60 years, who were neuropsychologically classified either as cognitively normal (n = 37), having mild cognitive impairment (Petersen criteria) (n = 22), or suffering from dementia (DSM-IV) (n = 30), compared with cognitively normal age-matched control subjects (n = 30). Plasma levels of Hcy, vitamins B12 and B6, folic acid, polymorphisms in genes related to Hcy metabolism (MTHFR, MTR, MTRR, and CBS) and silent cerebrovascular events were analyzed. Plasma levels of Hcy were increased in PD patients (P = 0.0001). There were no differences between the groups of patients. The brain vascular burden was similar among PD groups. There was no association between polymorphisms in the studied genes and the Hcy plasma levels or cognitive status in PD patients. We found no evidence for a direct relationship between Hcy plasma levels and cognitive impairment and dementia in PD. No indirect effect through cerebrovascular disease or genetic background was found either.
KW - Dementia
KW - Genetics
KW - Homocysteine
KW - Mild cognitive impairment
KW - Parkinson's disease
KW - White matter hyperintensities
UR - http://www.scopus.com/inward/record.url?scp=69849093882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69849093882&partnerID=8YFLogxK
U2 - 10.1002/mds.22522
DO - 10.1002/mds.22522
M3 - Article
C2 - 19452554
AN - SCOPUS:69849093882
SN - 0885-3185
VL - 24
SP - 1437
EP - 1444
JO - Movement Disorders
JF - Movement Disorders
IS - 10
ER -